Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. by Virdee, Satnam K et al.
Would primary healthcare professionals
prescribe a polypill to manage
cardiovascular risk? A qualitative
interview study
Satnam K Virdee,1 Sheila M Greenfield,1 Kate Fletcher,1 Richard J McManus,2
F D Richard Hobbs,2 Jonathan Mant3
To cite: Virdee SK,
Greenfield SM, Fletcher K,
et al. Would primary
healthcare professionals
prescribe a polypill to
manage cardiovascular risk?
A qualitative interview study.
BMJ Open 2013;3:e002498.
doi:10.1136/bmjopen-2012-
002498
▸ Prepublication history for
this paper are available
online. To view these files
please visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2012-002498).
Received 14 December 2012
Revised 19 February 2013
Accepted 22 February 2013
This final article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
2.0 Licence; see
http://bmjopen.bmj.com
For numbered affiliations see
end of article.
Correspondence to
Professor Sheila M Greenfield;
s.m.greenfield@bham.ac.uk
ABSTRACT
Objectives: A ‘polypill’ containing both blood
pressure-lowering and cholesterol-lowering drugs
could prevent up to 80% of cardiovascular disease
events. Since little is known about the attitudes of
primary healthcare professionals to use of such a pill
for cardiovascular disease prevention, this study aimed
to investigate opinions.
Design: Semistructured interviews were conducted
with participants. A qualitative description approach
was used to analyse and report the results.
Setting: Participants were recruited from nine primary
care practices in Birmingham.
Participants: Sixteen healthcare professionals
(11 primary care physicians and 5 practice nurses)
were selected through purposive sampling to maximise
variation of characteristics.
Outcome measures: Outcome measures for this
study were: the attitude of healthcare professionals
towards the use of a polypill for primary and secondary
cardiovascular disease prevention; their views on
monitoring the drug; and the factors influencing their
willingness to prescribe the medication.
Results: Healthcare professionals expressed
considerable concern over using a polypill for primary
prevention for all people over a specific age, although
there was greater acceptance of its use for secondary
prevention. Regularly monitoring patients taking the
polypill was deemed essential. Evidence of effectiveness,
patient risk level and potential medicalisation were key
determinants in willingness to prescribe such a pill.
Conclusions: Primary healthcare professionals have
significant concerns about the use of a polypill,
particularly in the prevention of cardiovascular disease in
people who are not regarded as being at ‘high risk’. If a
population-based polypill strategy is to be successfully
implemented, healthcare professionals will need to be
convinced of the potential benefits of a drug-based
population approach to prevention.
INTRODUCTION
Cardiovascular disease remains the major
cause of morbidity and mortality worldwide.1
There have been signiﬁcant advances in the
evidence base for cardiovascular disease pre-
vention, particularly regarding pharmaco-
logical interventions aimed at lowering blood
pressure2 3 and cholesterol.4 Guidelines rec-
ommend use of these agents for both second-
ary and primary prevention in people at raised
cardiovascular risk.5 6 However, repeated
surveys have shown many patients are not
ARTICLE SUMMARY
Article focus
▪ A ‘polypill’ containing several blood pressure-
lowering and cholesterol-lowering drugs has
large theoretical benefits in terms of reducing
cardiovascular morbidity. Short-term trials have
demonstrated its efficacy.
▪ Although small-scale surveys of physicians
suggest that the use of the polypill may be accept-
able to healthcare professionals, they have not pro-
vided detailed data on attitudes to the polypill.
▪ The aim of this study was to investigate the atti-
tude of healthcare professionals to the use of a
polypill for cardiovascular disease prevention.
Key messages
▪ There was considerable resistance towards the
use of a polypill for the prevention of cardiovas-
cular disease in people not regarded as being at
‘high risk’.
▪ Evidence of efficacy was judged important but
potential medicalisation and an ongoing need for
monitoring were significant issues for many
healthcare professionals.
▪ If a population-based polypill strategy is to be
introduced, significant barriers from profes-
sionals will need to be overcome.
Strengths and limitations of this study
▪ The study’s qualitative approach allowed a
detailed exploration of attitudes not possible in
quantitative surveys.
▪ Conversely, we cannot comment on how preva-
lent the views expressed in this study are in the
wider population of healthcare professionals.
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being treated as intensively as guidelines recommend.7–9
Furthermore, the majority of cardiovascular events occur
in people not at high risk using conventional risk calcula-
tors.10 Therefore, offering a ‘polypill’ to everyone over a
particular age (eg, 55) has been proposed.11 The original
idea involved a six-component pill (three blood pressure-
lowering agents; cholesterol-lowering agent; folate and
aspirin), but due to question marks over the efﬁcacy of
folate and the appropriateness of aspirin use for primary
prevention, this now typically involves a single daily com-
bined pill containing just blood pressure-lowering and
cholesterol-lowering agents. Since the idea was ﬁrst raised,
the evidence base for the potential role of a polypill has
grown. There is more evidence that the effect of blood
pressure lowering on cardiovascular risk is independent of
baseline blood pressure,12 and that reduction of low-
density lipoprotein cholesterol is beneﬁcial in those at low
risk of vascular disease.13 Meta-analysis of early trials show
that polypills do indeed lower blood pressure and serum
cholesterol levels.14
The polypill may also have a role in people with
known cardiovascular risk factors, since it may lead to
better patient adherence.15 16 Wald and Law11 estimate
adopting a polypill strategy could prevent 80% of strokes
and 88% of ischaemic heart disease events, with low risk
of adverse effects.
If used in the UK, it is likely that the polypill would
largely be prescribed and monitored within primary care.
Implementation would require considerable professional
engagement but to date there has been limited research
on the polypill’s professional acceptability. Three small
practitioner surveys have been conducted, but none in
the UK. Holt17 found from a survey of 17 New Zealand
primary care physicians almost all were familiar with the
polypill. They were keen on its simplicity and the likely
increased compliance, but disliked the lack of ﬂexibility
of the components and doses. More recently, Soliman et
al18 surveyed 58 Sri Lankan physicians and discovered a
high degree of acceptability of prescribing the polypill
for primary prevention and even higher for secondary
prevention. Viera et al’s19 ﬁndings from a survey of 952
US physicians also revealed relatively high acceptance,
but low agreement to minimal monitoring. Such surveys
while useful in gauging high-level opinions, cannot
explore detailed issues around acceptability in any depth.
The polypill has been used in a range of settings. This
paper reports on a study in Birmingham, UK, which
used a qualitative description approach20 21 to investi-
gate UK healthcare professionals’ that is, primary care
physicians’ and practice nurses’ attitude towards using
the polypill for cardiovascular disease prevention and
the drug’s practicality for monitoring and prescribing.
METHOD
Participants and sampling
Eleven Birmingham primary care practices agreed to
participate of 20 initially approached. Practices were
purposively selected to maximise variation in our
sample.22 They were chosen to represent different sizes
(number of full-time equivalent primary care physicians)
as practice size is known to affect prescribing behav-
iour.23 Practices were also selected to reﬂect different
levels of socioeconomic deprivation (Indices of Multiple
Deprivation (IMD) score of the practice area) since car-
diovascular need tends to be higher in practices based
in relatively deprived areas.24 The IMD score is a single
deprivation score combining a number of indicators cov-
ering a range of economic, social and housing issues.25
Scores were divided into quartiles, one representing the
least deprived areas and four the most. To contextualise
this work, Birmingham consists of a population of about
one million people including diverse ethnic groups with
one-third from a non-white background.26
The 56 primary care physicians and 22 practice nurses
in the 11 practices were sent a postal questionnaire
enquiring about their gender, ethnicity (2001 general
census ethnic categories)27 and year of qualiﬁcation,
together with a Beliefs about Medicines Questionnaire
(BMQ)-General.28 This includes two scales (General-
Harm and General-Overuse) to measure respondents’
attitudes to medicines in general. High scores indicate a
greater belief that medicines are harmful and overused.
This was used for sampling to ensure a range of views
on general medication usage. Since we wanted respon-
dents with extreme views and moderate beliefs and
there appeared to be different ways to interpret
scores,29–31 we divided respondents’ scores into tertiles,
scores between 8 and 15 being categorised as low,
16 and 22 as medium, and 23 and 40 as high.
Fifty-eight (74%) healthcare professionals returned a
completed BMQ-General. Respondents were sampled on
these scores as well as a maximum variety of individual
(occupation, gender, ethnicity, qualiﬁcation year) and
organisational (practice size, practice IMD score) charac-
teristics to allow a diversity of responses to emerge. Fifty
healthcare professionals (41 primary care physicians and
9 practice nurses) were selected and approached by
letter, and 16 (11 primary care physicians and 5 practice
nurses) agreed to interview across 9 practices.
Interviews
Semistructured interviews were used to elicit healthcare
professionals’ views as they provide an opportunity for
in-depth investigation of personal perspectives, detailed
understanding and chance for clariﬁcation.32 The inter-
view guide was developed through a discussion of the
polypill and cardiovascular disease literature by research
team members (SKV, SMG, KF and JM) and covered:
healthcare professionals’ understanding of the polypill;
their attitude towards its use; and prescribing and moni-
toring the drug. Ethical approval to conduct the inter-
views was granted by the Birmingham, East, North and
Solihull Research Ethics Committee (08/H1206/91).
Signed informed consent was obtained before the inter-
view. All interviews were carried out at the practices by
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one of the authors (SKV) from March to October 2009.
Interviews lasted between 30 and 60 min, were audio
recorded and transcribed verbatim.
Analysis
All transcripts were checked against the recording for
accuracy. As part of the process of respondent valid-
ation,33 healthcare professionals were sent a copy of
their transcript and a brief summary of the interview for
comments. Only one additional comment was made.
Although the advantages and disadvantages of this
process have been documented,34 since this is the ﬁrst
qualitative study on the polypill and it was a new
concept for interviewees, it was felt important to do this.
Throughout the analytic process each transcript was
compared with others to develop conceptualisations of
the possible relations between various pieces of data and
key areas.35 Interviews continued until the authors (SKV,
SMG and KF) agreed saturation had been achieved.
Transcripts and ﬁeld notes were read independently by
the authors (SKV, SMG and KF) and the subthemes
identiﬁed in each key area.20 These were discussed by
the multidisciplinary team of clinicians and non-
clinicians and a thematic coding framework was devel-
oped to code each transcript systematically. Framework
software was used to aid data organisation.36
RESULTS
Participants
There were similar numbers of men and women (table 1)
but all practice nurses were female and most primary care
physicians were male. Seven participants were from a
minority ethnic group (3 Indians; 1 White Irish; 1 Chinese
and 2 others). Most gained their professional qualiﬁcation
between 1970 and 1989. Participants had a full range of
attitudes towards medicines determined by their
BMQ-General score, but the four respondents with more
positive attitudes towards medicines were all practice
nurses.
Key areas
To facilitate comparison of comments and contextualise
subthemes, these are presented within each of the three
key areas: attitude towards the polypill; opinions on
monitoring and views on prescribing. The number of
respondents discussing each subtheme is reported
(denominator 16 participants)37 to contextualise the
ﬁndings and facilitate a comparison between respon-
dents. Interview extracts representative of each sub-
theme are shown in boxes 1–3. Comparison of the
subthemes did not reveal any relationship between
healthcare professionals’ characteristics and their views
on the polypill in managing cardiovascular risk.
Attitude towards the polypill
Healthcare professionals discussed their attitude towards
the polypill in terms of what they already knew and
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understood about it, and their thoughts about using
the medication for primary and secondary prevention
(box 1).
Knowledge and understanding of the polypill
The majority of respondents (11) understood the poly-
pill would be used for cardiovascular disease prevention,
whether for primary or secondary prevention or indeed
both, and that it would contain multiple ingredients.
Beyond this, their knowledge appeared limited. Most
(10) were uncertain about how they might use it, and
what drugs at what doses would be in it. Some (3) men-
tioned their knowledge was based on what they had read
in journals or seen in the media.
Use of the polypill for primary prevention
All interviewees (16) expressed concern about using the
polypill for primary prevention for everyone over a spe-
ciﬁc age. Most concerns were regarding: potential side-
effects; difﬁculty in identifying the ingredient(s) causing
side-effects and the built-in inability to titrate the ingre-
dients and dose. Other concerns raised were: unneces-
sary medicalisation of healthy people; lack of evidence
demonstrating effectiveness and the potential negative
impact on health-related behaviour, possibly leading to
complacency about leading a healthy lifestyle.
Box 1 Attitude towards the polypill
Knowledge and understanding of the polypill
Would be used for cardiovascular disease prevention
“[The polypill is]…hoping to reduce heart attacks and heart
disease and stroke and things like that really…regardless of
whether or not they have hypertension or ischemic heart disease
at the time.” (Primary care physician 4)
Uncertainty over aspects of polypill
“…you’re only going to put these people on primary prevention
if they’re at risk, aren’t you? It’s not for everybody is it?” (Primary
care physician 10)
Knowledge based on journals and media
“…I don’t know what the thinking behind the use of it is other
than what I’ve read in the national press.” (Primary care physician 8)
Use of the polypill for primary prevention
Concerns regarding actual polypill
“...one would intellectually feel that if you put five pills in a pill,
or four pills in a pill, more people are gonna react to it than if
you’ve got one pill.” (Primary care physician 3)
“I think you need titration, individual titration of different medi-
cations for individual people...so I can’t imagine that one pill will
work for everybody.” (Practice nurse 3)
Unnecessary medicalisation
“...its [the polypill] just another medication that you’d be com-
mitting the person to really...I just think it’s unnecessary. I think
we should be teaching people, well people, how to keep them-
selves well without offering them preventive things, in the way of
medication that is.” (Practice nurse 1)
Lack of evidence demonstrating effectiveness
“...if you’ve got evidence that it works, then it would be easy
for me to support. No, the evidence doesn’t exist.” (Primary care
physician 8)
Negative impact on patient lifestyle
“...it may very well give people a false sense of security...they’ll
continue to eat and drink too much, and smoke too much and
take the polypill...it may make no difference whatsoever to them.”
(Primary care physician 4)
May reduce cardiovascular disease risk
“...the possibilities are that it might reduce a population’s risk
of heart disease and stroke.” (Primary care physician 11)
“You would reach a population that you wouldn’t otherwise
reach, then you’re broadening the service you’re providing and
reducing cardiovascular risk.” (Primary care physician 8)
Should only be for those with risk factors
“It [the polypill] should only be for those at risk of a cardiovas-
cular attack...especially if there’s any history of cardiovascular
disease in the family.” (Primary care physician 2)
Use of the polypill for secondary prevention
Practical for patients
“...it just saves taking lots of tablets often: I think compliance
probably would be better.” (Practice nurse 5)
Lack of purpose
“...secondary prevention: I’m not so sure about because we are
supposed to be treating these patients anyway...so there is a
question really about...well the purpose really.” (Primary care
physician 11)
Box 2 Monitoring patients taking the polypill
Regular monitoring of patients
To check it is safe and effective
“...how will you know it’s actually being effective in terms of
reducing blood pressure if it’s not monitored?” (Practice nurse 3)
“...you need to see the side-effects...by monitoring. You need
to see whether they are developing anything else as well.”
(Primary care physician 7)
To screen for and encourage compliance
“...just to reassure [patients] that yes it is working, because I
think some people might stop taking it and then not bother
coming back, and then you’ve got problems with non-compliance
again.” (Practice nurse 5)
Medications are normally monitored
“…if someone’s on a drug then historically they are moni-
tored…not to monitor would be difficult.” (Practice nurse 4)
Polypill is only feasible with no monitoring
“I think the polypill is only feasible if there is no monitoring
associated with it...it’s probably only feasible if the dose is con-
sidered safe enough not to be monitored.” (Primary care phys-
ician 11)
Minimal monitoring of patients
Cause for concern
“That as a GP does not sit comfortably…if you’re prescribing
medication you have an ethical and a moral obligation to monitor
this person.” (Primary care physician 10)
“You don’t give people medicines without seeing what it’s
going to do: that’s pure negligent...” (Primary care physician 1)
Need to see the evidence
“So if the evidence was you don’t have to monitor a polypill
then I would say fine...but you’ve got to give me the evidence
that that’s an okay way to behave before I would consider that...”
(Primary care physician 8)
Would still monitor
“…if the advice was saying not to monitor I’d still want to…for
the patient’s sake and my sake.” (Primary care physician 6)
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Despite apprehension, half of healthcare professionals
(8) recognised the possible advantages of administering
a polypill to everyone over a speciﬁc age: mainly the
potential to reduce the risk of developing cardiovascular
disease at a population level. Hence a number (5) were
receptive towards a population approach, although the
majority (10) thought that the polypill should only be
given to those with cardiovascular disease risk factors.
Use of the polypill for secondary prevention
Of those interviewees (8) who discussed using the poly-
pill for secondary prevention, most (6) appeared posi-
tive believing it would be more practical for patients to
take it thereby improving compliance. However, a minor-
ity (two) questioned its value for secondary prevention
as it would merely be a combined replacement of
current cardiovascular disease medication.
Monitoring patients taking the polypill
Healthcare professionals reﬂected upon both regular
and minimal monitoring of patients taking the polypill
(box 2).
Regular monitoring of patients
Almost all participants (15) felt it was essential to regu-
larly monitor patients taking the polypill to: check the
medication was both safe and effective, especially as it is
a new drug; screen for and encourage patient compli-
ance and because of the perception that most pre-
scribed medications require some degree of monitoring.
Only one respondent felt regular monitoring was
unnecessary otherwise the polypill would become
unfeasible, although he highlighted the dose would
need to be considered safe enough.
Minimal monitoring of patients
The idea of minimal monitoring of patients taking the
polypill caused major unease among most healthcare
professionals (11), with two claiming such a strategy to
be negligent. Several (7) claimed they would need to
see evidence that minimal monitoring was deemed
appropriate before they could be convinced to adopt
this practice. Others (4) argued they would monitor
patients regularly even if the advice was that it was
unnecessary.
Prescribing the polypill
Although all healthcare professionals (16) would con-
sider prescribing the polypill, there appeared to be
several factors inﬂuencing their willingness. These could
be divided into four groups relating to: their personal
values; features of the drug; external issues and patient
factors (box 3).
Personal factors
For many respondents (10), personal beliefs regarding
unnecessary medicalisation meant they would not pre-
scribe the polypill without an indication in addition to
age alone.
Box 3 Prescribing the polypill
Personal factors
“...it’s not my ethos to medicate well people to prevent the
normal ageing process...” (Primary care physician 8)
“I just don’t believe that there’s a pill for every ill...later in life
you are probably going to develop some problems with your
blood pressure and maybe your cholesterol levels won’t stay the
same...I think you really have to live with them, you can’t expect
to be taking a tablet for every little change that’s happening in
your body.” (Practice nurse 1)
Drug factors (cost, monitoring, titration)
“...if it’s researched based, it’s shown to have fantastic results,
it’s cost effective...yes I would prescribe it.” (Practice nurse 2)
“...I would be happy prescribing it if I could watch people care-
fully for a while and see how they feel about it.” (Practice nurse 3)
“...unless there are different doses of combinations of polypills,
just giving one to somebody might not necessarily be the right
one for that person.” (Primary care physician 10)
External factors (evidence, guidance)
“...I would be happy [to prescribe the polypill], provided I’ve
got enough data to go on...I think everything hinges on that actu-
ally.” (Primary care physician 7)
“If our PCT and the Department of Health feel it’s a good thing,
then yes I would prescribe it.” (Practice nurse 2)
Patient factors (risk level, patient choice, previous side-effects,
existing cardiovascular disease, compliance, other medical condi-
tions medications, age)
“...patients would have to be selected on the basis of their
family history...if the family history contains ischaemic heart
disease then they’re the ones we should be picking first.”
(Primary care physician 4)
“I think we should give patients options. I don’t think we
should be saying “oh that is the one”. It’s very much a personal
choice for the patient.” (Primary care physician 5)
“Somebody who’s had an adverse reaction to any of those
things that are in it [the polypill], I honestly wouldn’t prescribe it,
just like you wouldn’t prescribe that drug to them.” (Primary care
physician 2)
“Secondary prevention patients – if we’re going to combine
some of the medications that they’re already on into a polypill so
they’re taking fewer tablets...they might be interested.” (Primary
care physician 1)
“...it very much depends on the type of patient...some people
will probably just be happier to take one pill rather than a
couple...people who have a problem with compliance...it would
be the right one for them...” (Primary care physician 5)
“...I don’t know if it is contraindicated with people with certain
conditions or people who are on certain medications like warfarin
for instance...that could be a barrier.” (Practice nurse 2)
“If they haven’t got any risk factors for cardiovascular disease,
I don’t think everybody over the age of 50 should be taking it.
I don’t think I’ll agree to that.” (Primary care physician 5)
“...[the polypill] couldn’t just be handed out to everybody over
the age of 50, unless the studies and research suggested that
there were no adverse effects and anyone could take the drug...
even if they didn’t have hypertension.” (Practice nurse 4)
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Drug factors
There were three important factors about the polypill
that were deemed to have an inﬂuence on whether or
not healthcare professionals would prescribe it: cost;
monitoring and titration. According to just less than half
(7) if the polypill was cost-effective for both patients and
the National Health Service, they would be more likely
to prescribe. However, others (5) stated cost would have
no bearing on their decision if the outcome was beneﬁ-
cial. Some respondents (6) claimed they would be more
willing to prescribe the polypill if they could monitor
patients. Quite a few (6) had concerns over the inability
to titrate it which meant they were reluctant about
prescribing.
External factors
Two external factors, evidence and guidance from the
Department of Health (DoH), seemed to impact on par-
ticipants’ decision to prescribe the polypill. Most (13)
claimed the evidence demonstrating the polypill to be
safe, effective and beneﬁcial would be a major determin-
ant in their judgement. Two said if the DoH endorsed
its prescribing, they would then do so.
Patient factors
There were several patient factors (risk level, patient
choice, previous side-effects, existing cardiovascular
disease, compliance, other medical conditions/medica-
tions) and one sociodemographic factor (age) that
inﬂuenced healthcare professionals’ views regarding
potential prescription of the polypill.
Most (10) claimed they would be more willing to pre-
scribe the medication as a preventative measure for
people with risk factors. Many (9) also believed that
their willingness would be inﬂuenced by the patient’s
choice to take the medication. A number of participants
(7) mentioned they would not offer the polypill to
patients who had experienced previous side-effects from
the individual ingredients. Several (6) believed they
would prescribe the polypill to patients on treatment for
existing cardiovascular disease as a replacement for prac-
tical reasons. Others (4) thought they would avoid medi-
cating these patients with the polypill since they require
titrated dosages. Where patients had problems comply-
ing with multiple medications, some respondents (4)
said they would be more likely to prescribe the polypill.
A few (4) also suggested they would be less keen to offer
the polypill to patients with complex medical conditions
or who were on certain medications due to possible
contraindications.
In terms of age, the majority of interviewees (10) did
not believe in prescribing the polypill to everyone over
50 years for primary prevention unless there were risk
factors. However, several (5) claimed that they would be
willing to offer the medication to this population regard-
less of their risk level, as long as the evidence demon-
strated it to be safe and effective. In fact, one healthcare
professional thought the age limit should be as low as
40 years for men. Some (4) said they would be happy to
prescribe the polypill for the elderly as it would be more
practical for them to take it, whereas others (2) main-
tained they would avoid it for this group due to pro-
blems of polypharmacy.
DISCUSSION
Summary of main findings
Healthcare professionals were sceptical about the role of
a polypill. A major concern was they did not feel the evi-
dence base for a polypill had been established. They
were particularly reluctant to prescribe on the basis of
age and felt ongoing monitoring of blood pressure and
cholesterol would be required. The inability to titrate
dose in the polypill was seen as a further disadvantage.
There was greater willingness to consider its use for sec-
ondary prevention, but with the same provisos about
wanting to continue monitoring and with concerns
about the inability to adjust the dose.
Comparison with existing literature
As with a previous survey study,18 we found healthcare
professionals were more accepting of a polypill for sec-
ondary prevention perhaps because for those with exist-
ing cardiovascular disease there is a greater perceived
need for medication. However, we discovered a lower
level of acceptance for primary prevention, with more
concerns regarding the pill itself. This may reﬂect typic-
ally slower uptake of new drugs by primary care physi-
cians in the UK compared with other countries,38 with
many describing themselves as ‘cautious’ or ‘conserva-
tive’ in their prescribing behaviour.39
In our study, healthcare professionals disliked the
concept of minimal monitoring of patients taking the
polypill, a ﬁnding consistent with earlier studies.18 19
This reﬂects current practice where patients are moni-
tored for a number of reasons, including side-effects,
effectiveness and compliance. Nevertheless, current
National Institute for Health and Clinical Excellence
guidelines on lipid-lowering therapy for primary preven-
tion do not recommend monitoring,6 so attitudes may
change.
Strengths and limitations
A study strength is that all interviews were carried out by
a single researcher thereby ensuring consistency.40 The
researcher was non-medical, and healthcare profes-
sionals’ responses may have been different if the
researcher had been a clinician.
The study’s qualitative approach allowed an in-depth
exploration of attitudes not possible in quantitative
surveys. Study participants were recruited from a single
major city. Sixteen of the 50 approached were inter-
viewed and it is not possible to comment on how preva-
lent the views expressed in this study are in the wider
population of primary healthcare professionals or those
from other healthcare systems. Also, what respondents
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suggested they would do is not necessarily what they
would actually do in reality.
Although the aim of qualitative research is not to be
generalisable,41 we did have a representative sample of
respondents across gender and ethnicity. Our sample
size was also sufﬁcient to achieve saturation.42
Implications
This study suggests despite potential acceptance of use
of a polypill for secondary prevention, healthcare profes-
sionals interviewed remained concerned that monitoring
should continue. With regard to primary prevention,
there was considerable resistance to a population strat-
egy offering the polypill to everyone over a certain age.
This reﬂected both a concern about the lack of empir-
ical evidence of the polypill’s effectiveness and safety,
and a concern regarding medicalisation. If a polypill is
to be used in this way, based on our respondents’ views
it is likely healthcare professionals would need to be
convinced about the potential beneﬁts of a drug-based
population approach to prevention.
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